Veru Stock Price, News & Analysis

Veru Inc. (NASDAQ: VERU) is a late clinical stage biopharmaceutical company focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. According to the company’s disclosures, Veru’s drug development program centers on two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm is described as a selective androgen receptor modulator (SARM) being developed to make weight reduction by GLP‑1 receptor agonist (GLP‑1 RA) drugs more tissue selective for loss of fat and preservation of lean mass, with the goal of improving body composition and physical function. Sabizabulin is a microtubule disruptor being developed for the treatment of inflammation in atherosclerotic cardiovascular disease.

Veru is listed on the NASDAQ Capital Market under the ticker symbol VERU, as confirmed in multiple Form 8‑K filings, which also show that its common stock has a par value of $0.01 per share. The company has described itself in recent press releases as a late clinical stage biopharmaceutical business, reflecting that its lead product candidates are in Phase 2 development and other late-stage clinical activities rather than commercial stages.

Core pipeline and therapeutic focus

The company’s pipeline, as described in its news releases, is concentrated in two main product candidates:

• Enobosarm – a selective androgen receptor modulator being developed as a next generation drug that, when used with GLP‑1 RA drugs for weight reduction, aims to make weight loss more selective for fat while preserving lean mass and physical function. Veru refers to this as an obesity and chronic weight management program, with an emphasis on body composition and muscle preservation.
• Sabizabulin – a microtubule disruptor being developed for the treatment of inflammation in atherosclerotic cardiovascular disease. Company communications consistently describe sabizabulin in this context, highlighting its intended role in inflammatory cardiovascular conditions.

Veru’s public statements emphasize cardiometabolic disease, obesity, and inflammation as key therapeutic areas. The company’s communications describe enobosarm as a drug candidate intended to make GLP‑1 RA‑mediated weight loss more selective for fat loss and to preserve lean mass, with expected improvements in body composition and physical function compared to GLP‑1 RA monotherapy.

Enobosarm obesity and chronic weight management program

Veru has reported results from its Phase 2b QUALITY clinical study and a subsequent Maintenance Extension study evaluating enobosarm in older patients receiving semaglutide (a GLP‑1 RA) for weight reduction or chronic weight management. The QUALITY trial is described as a multicenter, double‑blind, placebo‑controlled, randomized, dose‑finding clinical trial that evaluated enobosarm 3 mg, enobosarm 6 mg, or placebo in 168 older patients (≥60 years of age) receiving semaglutide.

According to the company, the Phase 2b QUALITY study showed that enobosarm in combination with semaglutide preserved lean mass and led to greater loss of fat mass compared to semaglutide plus placebo during a 16‑week active weight loss period. Veru reports that tissue composition of weight loss differed between groups, with the placebo plus semaglutide group losing both lean and fat mass, while the enobosarm 3 mg plus semaglutide group’s weight loss was characterized as 0% lean mass and 100% fat mass in the company’s summary.

Physical function was measured using a Stair Climb Test. Company disclosures state that a responder analysis using a greater than 10% decline in stair climb power as a cutoff demonstrated that a higher proportion of patients in the placebo plus semaglutide group experienced clinically significant declines in stair climb power compared with those receiving enobosarm plus semaglutide. Veru characterizes this as evidence that preserving lean mass with enobosarm translated into a lower proportion of patients experiencing a decline in physical function.

In the Maintenance Extension portion of the QUALITY study, after semaglutide was discontinued, patients continued on placebo or enobosarm monotherapy for 12 weeks. Veru reports that enobosarm monotherapy significantly reduced body weight regain, prevented fat regain, and preserved lean mass compared to placebo. The company states that by the end of the combined study period, regimens including enobosarm plus semaglutide followed by enobosarm monotherapy were more effective in preserving lean mass and maintaining greater loss of fat mass than placebo plus semaglutide followed by placebo.

Regulatory feedback and planned PLATEAU study

Veru has announced that it held a meeting with the U.S. Food and Drug Administration (FDA) regarding the regulatory pathway for enobosarm in combination with GLP‑1 RA therapy for obesity. Based on the company’s description of FDA feedback, incremental weight loss when enobosarm is added to GLP‑1 RA treatment, compared to GLP‑1 RA alone, is described as an acceptable primary endpoint to support potential approval, and enobosarm 3 mg has been confirmed by the FDA as an acceptable dosage for future development.

Building on this feedback and the QUALITY study results, Veru has outlined plans for a Phase 2b PLATEAU clinical study. Company communications describe PLATEAU as a trial designed to evaluate the effect of enobosarm 3 mg on total body weight, physical function, and safety in patients with obesity who are initiating GLP‑1 RA treatment for weight reduction. Veru states that the primary efficacy endpoint is the percent change from baseline in total body weight at 72 weeks, with interim analysis at 36 weeks to assess changes in lean body mass and fat mass by DEXA scan. Key secondary endpoints are described as including total fat mass, total lean mass, physical function (stair climb test), bone mineral density, and patient‑reported outcome questionnaires for physical function.

The company characterizes the PLATEAU study as being designed to assess whether enobosarm treatment can address the weight loss plateau observed in patients with obesity receiving GLP‑1 RA therapy, with the goal of achieving clinically meaningful incremental weight reduction while preserving muscle mass and physical function.

Modified release enobosarm formulation and collaboration

Veru has also announced the selection of a novel modified release oral formulation of enobosarm for chronic weight loss management. In a single‑dose, open‑label pilot pharmacokinetic study, the company reports that the modified release formulation of enobosarm 3 mg demonstrated a target release profile characterized by a reduced maximum plasma concentration (Cmax), a delayed time to maximum plasma concentration (Tmax), a distinct secondary peak plasma concentration, and a similar extent of absorption (AUC) compared to historical values for immediate‑release enobosarm capsules.

The company states that this modified release formulation was developed in collaboration with Laxxon Medical using Laxxon’s proprietary SPID‑Technology and an additive manufacturing process. Veru describes the manufacturing process for the novel oral formulation as being protected by issued global patents with protection through 2037, with additional patent applications filed for the modified release formulation and potential expiry dates, if issued, extending to 2046. Veru has indicated that this formulation is planned to be available for further clinical studies and potential commercialization, subject to regulatory approval.

Capital markets activity and listing status

Veru’s SEC filings describe several recent corporate and capital markets actions. In an August 2025 Form 8‑K, the company reported that it filed Articles of Amendment to effect a 1‑for‑10 reverse stock split of its issued and outstanding common stock, effective at a specified time in August 2025. The filing explains that the reverse stock split converted every 10 shares of common stock into one share, without changing the number of authorized shares or the par value, and that fractional shares would not be issued, with shareholders instead receiving cash in lieu of fractional shares. The company noted that its common stock would continue to trade on the Nasdaq Capital Market under the symbol VERU on a split‑adjusted basis.

In a separate Form 8‑K, Veru disclosed that it received a letter from the Nasdaq Listing Qualifications Department in August 2025 stating that the company had regained compliance with the minimum bid price requirement for continued listing on Nasdaq under Listing Rule 5550(a)(2), closing a prior deficiency matter related to the minimum bid price.

Another Form 8‑K filed in October 2025 describes an underwritten public offering of common stock (or pre‑funded warrants in lieu of common stock) and accompanying Series A and Series B warrants. The company reported that it entered into an underwriting agreement with Canaccord Genuity LLC, as representative of the underwriters, for the offering of shares and warrants, with expected net proceeds of approximately $23.4 million after underwriting discounts and estimated expenses. Veru’s related press release states that the company intends to use net proceeds primarily to fund development of enobosarm, with a focus on Phase 2b PLATEAU clinical study activities, and for working capital and general corporate purposes.

Other corporate and financial disclosures

Veru’s Form 8‑K filings and press releases also describe other corporate events. In September 2025, the company reported entering into a Settlement Agreement and Release with Onconetix, Inc. (formerly Blue Water Vaccines Inc.) related to promissory notes issued to Veru under an asset purchase agreement. The settlement involved a combination of cash, shares of Series D Convertible Preferred Stock of Onconetix, and warrants to purchase Onconetix common stock, which the company accepted in full satisfaction of amounts due under the notes. Veru noted that there can be no assurance as to whether or when it will receive cash proceeds from the securities received.

In its fiscal 2025 third quarter and full‑year press releases, Veru provided high‑level financial information, including research and development and general and administrative expenses, operating loss, and net loss from continuing operations. These communications also reiterated the company’s focus on advancing enobosarm and sabizabulin within cardiometabolic and inflammatory disease indications.

Business model and stage of development

Based on the company’s own descriptions, Veru’s business model is centered on clinical development of novel small molecule drug candidates in cardiometabolic and inflammatory disease areas. The company characterizes itself as late clinical stage, reflecting that its lead program, enobosarm, has completed Phase 2b studies and is being prepared for further clinical development in obesity and chronic weight management settings, and that sabizabulin is in development for inflammation in atherosclerotic cardiovascular disease.

Veru’s disclosures emphasize regulatory interactions, clinical trial design, and intellectual property protection as key elements of its strategy. The company’s SEC filings and press releases highlight ongoing and planned clinical trials, FDA meetings, and capital raising activities to support these programs. Investors researching VERU stock can review these materials, including Forms 8‑K and press releases, for detailed information about the company’s clinical progress, regulatory status, and financing transactions.

Frequently asked questions about Veru Inc. (VERU)

• What does Veru Inc. do?
  Veru Inc. is a late clinical stage biopharmaceutical company focused on developing medicines for cardiometabolic and inflammatory diseases. Its drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin, as described in multiple company press releases.
• What are Veru’s main drug candidates?
  According to the company, Veru’s main drug candidates are enobosarm, a selective androgen receptor modulator being developed to make GLP‑1 RA‑mediated weight loss more selective for fat loss while preserving lean mass, and sabizabulin, a microtubule disruptor being developed for the treatment of inflammation in atherosclerotic cardiovascular disease.
• On which exchange does VERU trade?
  Form 8‑K filings state that Veru’s common stock is listed on the Nasdaq Capital Market under the trading symbol VERU, with a par value of $0.01 per share.
• What is the focus of the enobosarm obesity program?
  The enobosarm obesity program, as described by Veru, aims to use enobosarm in combination with GLP‑1 RA drugs to augment fat loss and prevent muscle loss in patients with obesity receiving GLP‑1 RA therapy, with the goal of improving body composition and physical function and addressing weight loss plateaus.
• What was the Phase 2b QUALITY study?
  The Phase 2b QUALITY study was a multicenter, double‑blind, placebo‑controlled, randomized, dose‑finding clinical trial of enobosarm 3 mg, enobosarm 6 mg, or placebo in older patients receiving semaglutide for weight reduction or chronic weight management. Veru reports that the study showed preservation of lean mass, greater fat loss, and favorable physical function outcomes with enobosarm plus semaglutide compared to placebo plus semaglutide.
• What is the PLATEAU clinical study?
  Veru has described PLATEAU as a planned Phase 2b clinical trial evaluating enobosarm 3 mg in patients with obesity who are initiating GLP‑1 RA treatment. The primary endpoint is the percent change from baseline in total body weight at 72 weeks, with secondary endpoints including body composition and physical function measures.
• Has Veru changed its share structure recently?
  Yes. In August 2025, Veru filed Articles of Amendment to effect a 1‑for‑10 reverse stock split of its issued and outstanding common stock, as disclosed in a Form 8‑K. The reverse split adjusted the number of shares outstanding but did not change the number of authorized shares or the par value.
• Is Veru in compliance with Nasdaq listing requirements?
  A Form 8‑K dated August 27, 2025 reports that Nasdaq notified Veru it had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), closing a prior deficiency matter related to the minimum bid price.
• How is Veru funding its clinical programs?
  Veru’s October 2025 Form 8‑K and related press release describe an underwritten public offering of common stock, pre‑funded warrants, and accompanying Series A and Series B warrants, with expected net proceeds of approximately $23.4 million. The company has stated that it intends to use the net proceeds primarily to fund development of enobosarm, including Phase 2b PLATEAU study activities, and for working capital and general corporate purposes.
• What stage is sabizabulin in?
  Company press releases consistently describe sabizabulin as a late-stage novel small molecule microtubule disruptor being developed for the treatment of inflammation in atherosclerotic cardiovascular disease. Specific trial stages and designs are referenced generally in these communications but are not detailed in the provided excerpts.